Abstract
A remarkable diversity of psychiatric and neurological disorders have been associated with dysfunction of dopamine (DA)-containing neurons, including schizophrenia, bipolar disorder (BD), Parkinsons disease (PD), and restless legs syndrome (RLS). In such disorders, transmission in discrete DA pathways may range from hypoactivation to hyperactivation of DA receptors, particularly those of the D2 subtype, providing the rationale for treatment approaches that activate or block D2 receptors, respectively. However, full agonists or pure D2 receptor antagonists may not be optimal therapeutic approaches for their respective disorders for a number of reasons, including an inability to restore the aberrant DA pathways to a normal level of basal tone. D2 receptor partial agonists (D2PAs) are proposed to stabilize activity in DA pathways by dampening excessive (and/or by restoring deficient) D2 receptor stimulation thereby shepherding DA neurons back to a desired level of basal activity. Stabilizing aberrant DA activity without disrupting nondysfunctional DA neurons may provide a potentially improved approach for treating DA disorders. The status of DA D2PAs and their potential application to schizophrenia, BD, PD, and RLS is reviewed. Preclinical and clinical evidence supports the idea that dysfunctions of D2 receptors contribute to these CNS disorders. Diseases in which both hyper- and hypofunction of DA pathways are present may be particularly promising, and challenging, targets for D2PAs. Furthermore, different DA disorders may respond optimally to D2PAs with differing levels of intrinsic activity, with “DA deficiency” diseases responding more effectively to higher intrinsic activity D2PAs than “DA hyperactivation” diseases. Overall, current evidence supports the conclusion that D2PAs have significant potential as improved CNS therapies relative to classic full agonists and antagonists at D2 receptors.
Keywords: Dopamine, DA: D2 Receptor Partial Agonist, D2 PA, Dopamine Stabilizer, Aripiprazole, Bifeprunox, periodic limb movements in sleep (PLMS), Aplindore, Schizophrenia, Bipolar Disorder
Current Topics in Medicinal Chemistry
Title: D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function
Volume: 8 Issue: 12
Author(s): John H. Kehne, Terrance H. Andree and Julia N. Heinrich
Affiliation:
Keywords: Dopamine, DA: D2 Receptor Partial Agonist, D2 PA, Dopamine Stabilizer, Aripiprazole, Bifeprunox, periodic limb movements in sleep (PLMS), Aplindore, Schizophrenia, Bipolar Disorder
Abstract: A remarkable diversity of psychiatric and neurological disorders have been associated with dysfunction of dopamine (DA)-containing neurons, including schizophrenia, bipolar disorder (BD), Parkinsons disease (PD), and restless legs syndrome (RLS). In such disorders, transmission in discrete DA pathways may range from hypoactivation to hyperactivation of DA receptors, particularly those of the D2 subtype, providing the rationale for treatment approaches that activate or block D2 receptors, respectively. However, full agonists or pure D2 receptor antagonists may not be optimal therapeutic approaches for their respective disorders for a number of reasons, including an inability to restore the aberrant DA pathways to a normal level of basal tone. D2 receptor partial agonists (D2PAs) are proposed to stabilize activity in DA pathways by dampening excessive (and/or by restoring deficient) D2 receptor stimulation thereby shepherding DA neurons back to a desired level of basal activity. Stabilizing aberrant DA activity without disrupting nondysfunctional DA neurons may provide a potentially improved approach for treating DA disorders. The status of DA D2PAs and their potential application to schizophrenia, BD, PD, and RLS is reviewed. Preclinical and clinical evidence supports the idea that dysfunctions of D2 receptors contribute to these CNS disorders. Diseases in which both hyper- and hypofunction of DA pathways are present may be particularly promising, and challenging, targets for D2PAs. Furthermore, different DA disorders may respond optimally to D2PAs with differing levels of intrinsic activity, with “DA deficiency” diseases responding more effectively to higher intrinsic activity D2PAs than “DA hyperactivation” diseases. Overall, current evidence supports the conclusion that D2PAs have significant potential as improved CNS therapies relative to classic full agonists and antagonists at D2 receptors.
Export Options
About this article
Cite this article as:
Kehne H. John, Andree H. Terrance and Heinrich N. Julia, D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function, Current Topics in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/156802608785161394
DOI https://dx.doi.org/10.2174/156802608785161394 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of the Transglutaminase Enzymes in the Nervous System and their Possible Involvement in Neurodegenerative Diseases
Current Medicinal Chemistry The Influence of Erythropoietin and Proinflammatory Cytokines in the Development of Cerebral Palsy
Vascular Disease Prevention (Discontinued) Role of Artificial Intelligence Techniques (Automatic Classifiers) in Molecular Imaging Modalities in Neurodegenerative Diseases
Current Alzheimer Research Purine Molecules as Hypnogenic Factors Role of Adenosine, ATP, and Caffeine
Central Nervous System Agents in Medicinal Chemistry Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Progress in the Development of Melanocortin Receptor Selective Ligands
Current Pharmaceutical Design Binding of the PET Radiotracer [<sup>18</sup>F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice
Current Alzheimer Research Female Infertility and Assisted Reproduction: Impact of Oxidative Stress-- An Update
Current Women`s Health Reviews A Retrospective Study on <i>Gloriosa superba</i> and Its Main Active Constituents
The Natural Products Journal F508del-CFTR Rescue: A Matter of Cell Stress Response
Current Pharmaceutical Design Splice Modification to Restore Functional Dystrophin Synthesis in Duchenne Muscular Dystrophy
Current Pharmaceutical Design Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy The Endocannabinoid System and Huntingtons Disease
Current Drug Targets - CNS & Neurological Disorders Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design The Capsaicin Paradox: Pain Relief by an Algesic Agent
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology